AU2021290997C1 - Heterodimeric relaxin fusions and uses thereof - Google Patents

Heterodimeric relaxin fusions and uses thereof Download PDF

Info

Publication number
AU2021290997C1
AU2021290997C1 AU2021290997A AU2021290997A AU2021290997C1 AU 2021290997 C1 AU2021290997 C1 AU 2021290997C1 AU 2021290997 A AU2021290997 A AU 2021290997A AU 2021290997 A AU2021290997 A AU 2021290997A AU 2021290997 C1 AU2021290997 C1 AU 2021290997C1
Authority
AU
Australia
Prior art keywords
ser
val
pro
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021290997A
Other languages
English (en)
Other versions
AU2021290997A1 (en
AU2021290997B2 (en
Inventor
Peng KE
Esther Marie Martin
Monika Anna Papworth
Judy Christiane Paterson
Isabelle SERMADIRAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2021290997A1 publication Critical patent/AU2021290997A1/en
Publication of AU2021290997B2 publication Critical patent/AU2021290997B2/en
Application granted granted Critical
Publication of AU2021290997C1 publication Critical patent/AU2021290997C1/en
Priority to AU2024200074A priority Critical patent/AU2024200074B2/en
Priority to AU2025252658A priority patent/AU2025252658A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021290997A 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof Active AU2021290997C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024200074A AU2024200074B2 (en) 2020-06-17 2024-01-05 Heterodimeric relaxin fusions and uses thereof
AU2025252658A AU2025252658A1 (en) 2020-06-17 2025-10-20 Heterodimeric relaxin fusions and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17
US63/040,250 2020-06-17
PCT/EP2021/066309 WO2021255127A1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200074A Division AU2024200074B2 (en) 2020-06-17 2024-01-05 Heterodimeric relaxin fusions and uses thereof

Publications (3)

Publication Number Publication Date
AU2021290997A1 AU2021290997A1 (en) 2023-02-09
AU2021290997B2 AU2021290997B2 (en) 2023-10-12
AU2021290997C1 true AU2021290997C1 (en) 2024-01-04

Family

ID=76584509

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2021290997A Active AU2021290997C1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof
AU2024200074A Active AU2024200074B2 (en) 2020-06-17 2024-01-05 Heterodimeric relaxin fusions and uses thereof
AU2025252658A Pending AU2025252658A1 (en) 2020-06-17 2025-10-20 Heterodimeric relaxin fusions and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024200074A Active AU2024200074B2 (en) 2020-06-17 2024-01-05 Heterodimeric relaxin fusions and uses thereof
AU2025252658A Pending AU2025252658A1 (en) 2020-06-17 2025-10-20 Heterodimeric relaxin fusions and uses thereof

Country Status (17)

Country Link
US (3) US11795205B2 (https=)
EP (1) EP4168434A1 (https=)
JP (2) JP7797423B2 (https=)
KR (1) KR20230024994A (https=)
CN (1) CN115916813B (https=)
AR (1) AR125007A1 (https=)
AU (3) AU2021290997C1 (https=)
BR (1) BR112022025019A2 (https=)
CA (1) CA3186143A1 (https=)
CL (1) CL2022003578A1 (https=)
CO (1) CO2023000038A2 (https=)
CR (1) CR20230015A (https=)
EC (1) ECSP23002960A (https=)
IL (1) IL298786A (https=)
MX (1) MX2022016340A (https=)
TW (1) TWI899263B (https=)
WO (1) WO2021255127A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CA3252059A1 (en) 2022-05-07 2025-07-07 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Relaxin fusion protein or analogue and its medical use
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
EP4630036A1 (en) 2022-12-09 2025-10-15 Astrazeneca AB Dosing regimens using heterodimeric relaxin fusions
CN120813595A (zh) 2023-03-03 2025-10-17 阿斯利康(瑞典)有限公司 包含异源二聚体松弛素融合蛋白的药物制剂及其用途
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058768A1 (en) * 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013004607A1 (en) * 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2014102179A1 (en) * 2012-12-27 2014-07-03 Bayer Pharma Aktiengesellschaft Fusion polypeptides and uses thereof
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US8389475B2 (en) 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
CA3244731A1 (en) * 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
PT3387019T (pt) * 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058768A1 (en) * 2010-11-05 2012-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2013004607A1 (en) * 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2014102179A1 (en) * 2012-12-27 2014-07-03 Bayer Pharma Aktiengesellschaft Fusion polypeptides and uses thereof
WO2018138170A1 (en) * 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
US20250230214A1 (en) 2025-07-17
IL298786A (en) 2023-02-01
BR112022025019A2 (pt) 2022-12-27
AU2025252658A1 (en) 2025-11-13
US20220017591A1 (en) 2022-01-20
ECSP23002960A (es) 2023-03-31
JP2026053559A (ja) 2026-03-25
US20240025958A1 (en) 2024-01-25
AU2021290997A1 (en) 2023-02-09
MX2022016340A (es) 2023-01-24
AU2021290997B2 (en) 2023-10-12
CL2022003578A1 (es) 2023-06-09
US11795205B2 (en) 2023-10-24
TWI899263B (zh) 2025-10-01
WO2021255127A1 (en) 2021-12-23
CN115916813A (zh) 2023-04-04
TW202214673A (zh) 2022-04-16
AR125007A1 (es) 2023-05-31
CA3186143A1 (en) 2021-12-23
AU2024200074B2 (en) 2025-11-27
JP2023530335A (ja) 2023-07-14
KR20230024994A (ko) 2023-02-21
JP7797423B2 (ja) 2026-01-13
AU2024200074A1 (en) 2024-01-25
CR20230015A (es) 2023-02-17
EP4168434A1 (en) 2023-04-26
US12187774B2 (en) 2025-01-07
CO2023000038A2 (es) 2023-01-16
CN115916813B (zh) 2026-03-24

Similar Documents

Publication Publication Date Title
AU2021290997C1 (en) Heterodimeric relaxin fusions and uses thereof
US11845782B2 (en) Relaxin fusion polypeptides and uses thereof
KR102455680B1 (ko) 신규 항인간 Tie2 항체
AU2019248547B2 (en) Anti-TREM-1 antibodies and uses thereof
JP2018064559A (ja) 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド
US20250295737A1 (en) Treatment Using Heterodimeric Relaxin Fusions
US11970524B2 (en) Recombinant ROBO2 proteins, compositions, methods and uses thereof
TW202426037A (zh) 使用異二聚鬆弛素融合物之治療方法
EA049488B1 (ru) Гетеродимерные слитые продукты на основе релаксина и пути их применения
EA052557B1 (ru) Лечение с применением гетеродимерных слитых продуктов на основе релаксина
TW202600604A (zh) Ghr激動型抗體及其應用
CN118434437A (zh) 使用异源二聚体松弛素融合物进行的治疗
CN120457144A (zh) 产生作为α7烟碱乙酰胆碱受体的沉默和正变构调节剂的抗体

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 SEP 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 SEP 2023

FGA Letters patent sealed or granted (standard patent)